Heba M. Eltahir
- Pharmacology top 10%
- Drug-Induced Hepatotoxicity and Protection 4
-
- Liver physiology and pathology 3
-
- Endoplasmic Reticulum Stress and Disease 3
-
- Fibroblast Growth Factor Research 3
-
- Liver Disease Diagnosis and Treatment 4
-
- COVID-19 Clinical Research Studies 2
-
- COVID-19 and healthcare impacts 2
-
- Cancer, Hypoxia, and Metabolism 2
- Co-authors
- Mekky M. AbouziedVolkmar GieselmannSebastian FrankenMaiiada NazmyAshraf HamedAhmed WahidMichael Atef FawzyHossein M. Elbadawy
- Journals
- Journal of Biological Chemistry (2 papers)SHILAP Revista de lepidopterología (1 paper)BMC Public Health (1 paper)
- Partner nations
- Saudi ArabiaEgyptGermany
In The Last Decade
Heba M. Eltahir
28 papers receiving 376 citations
Peers
Comparison fields: 5 of 94
- Pharmacology 77
- Molecular Medicine 20
- Hepatology 32
- Cell Biology 36
- Molecular Biology 150
Countries citing papers authored by Heba M. Eltahir
This map shows the geographic impact of Heba M. Eltahir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heba M. Eltahir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heba M. Eltahir more than expected).
Fields of papers citing papers by Heba M. Eltahir
This network shows the impact of papers produced by Heba M. Eltahir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heba M. Eltahir. The network helps show where Heba M. Eltahir may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Heba M. Eltahir, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 10 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 0 | |
| 6 | 2024 | 1 | |
| 7 | 2024 | 3 | |
| 8 | 2023 | 16 | |
| 9 | 2023 | 2 | |
| 10 | 2022 | 8 | |
| 11 | 2022 | 2 | |
| 12 | 2020 | 5 | |
| 13 | 2020 | 12 | |
| 14 | 2019 | 36 | |
| 15 | 2017 | 24 | |
| 16 | 2016 | 47 | |
| 17 | 2015 | 23 | |
| 18 | 2014 | 31 | |
| 19 | 2009 | 20 | |
| 20 | 2005 | 32 |
About Heba M. Eltahir
Heba M. Eltahir is a scholar working on Hepatology, Pharmacology and Cancer Research, having authored 32 papers that have together received 379 indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (4 papers), Drug-Induced Hepatotoxicity and Protection (4 papers), Fibroblast Growth Factor Research (3 papers), Liver physiology and pathology (3 papers), Endoplasmic Reticulum Stress and Disease (3 papers), COVID-19 Clinical Research Studies (2 papers), COVID-19 and healthcare impacts (2 papers) and Cancer, Hypoxia, and Metabolism (2 papers). The work is most often cited by research in Pharmacology (77 citations), Molecular Medicine (20 citations) and Hepatology (32 citations). Heba M. Eltahir has collaborated with scholars based in Saudi Arabia, Egypt and Germany. Frequent co-authors include Mekky M. Abouzied, Volkmar Gieselmann, Sebastian Franken, Maiiada Nazmy, Ashraf Hamed, Ahmed Wahid, Michael Atef Fawzy, Hossein M. Elbadawy, Ahmed M. Shehata and Ashraf Taye. Their work appears in journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and BMC Public Health.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.